Upadacitinib is associated with clinical response and steroid‐free remission for children and adolescents with inflammatory bowel disease

医学 炎症性肠病 溃疡性结肠炎 内科学 钙蛋白酶 胃肠病学 粪钙保护素 不利影响 回顾性队列研究 疾病
作者
Joseph Runde,Kelsey Ryan,Joseph Hirst,Jonathan Lebowitz,Wenya Chen,Jeffrey B. Brown,Jennifer Strople
出处
期刊:Journal of Pediatric Gastroenterology and Nutrition [Lippincott Williams & Wilkins]
卷期号:80 (1): 133-140 被引量:8
标识
DOI:10.1002/jpn3.12408
摘要

Abstract Objective Upadacitinib, an oral Janus kinase inhibitor (JAKi), is approved for inflammatory bowel disease (IBD) in adults. As on‐label use will face significant delay in pediatrics, a real‐world understanding of safety and efficacy in children is critical. Methods This is a single‐center retrospective cohort of pediatric subjects (ages 9–20 years) with a diagnosis of IBD initiated on upadacitinib. The primary outcome was clinical response following induction (decrease of ≥20 points in the Pediatric Ulcerative Colitis Activity Index [PUCAI] or ≥12.5 points for the Pediatric Crohn's Disease Activity Index [PCDAI]). Secondary outcomes included steroid‐free clinical remission (SF‐CR) following induction and at Week 24 (PUCAI or PCDAI ≤10), post‐induction mucosal response and remission (Mayo for ulcerative colitis [UC]/IBD‐unclassified [IBD‐U] and simple‐endoscopic scoring for CD), and improvement in calprotectin and C‐reactive protein (CRP) post‐induction. Monitoring for adverse events was recorded. Results Twenty subjects (40% female with a median age of 16.3 years; 3 CD, 13 UC, 4 IBD‐U) were initiated on upadacitinib. Clinical response at Week 8 (UC/IBD‐U) and Week 12 (CD), was achieved in 90% (18/20). SF‐CR was seen in 75% (16/20) following induction and maintained in 65% (11/17) reaching Week 24 of therapy. In subjects with UC/IBD‐U (17), PUCAI was significantly improved at Weeks 8 and 24. Calprotectin post‐induction showed a significant downtrend, whereas CRP did not. Endoscopic response was noted in seven of the eight cases, with three achieving endoscopic remission. One patient underwent subtotal colectomy after 2 weeks of upadacitinib induction. Another patient stopped therapy following the creation of a diverting ileostomy secondary to rectal perforation experienced following manual dilation of a rectal stricture. No new safety signals were reported. Conclusion Therapeutic options for children with IBD remain limited. In cases refractory to approved agents, our experience suggests that upadacitinib is effective with no new safety signals in a small subset of patients with IBD (ages 9–20 years) treated at a children's hospital.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
写得出发的中完成签到,获得积分10
1秒前
2秒前
饿饿饿饿发布了新的文献求助30
3秒前
3秒前
今后的应助被白华苍松采纳,获得10
4秒前
科研通AI65的应助被DW采纳,获得10
5秒前
5秒前
酵母君发布了新的文献求助10
7秒前
虾片完成签到,获得积分10
7秒前
思源的应助被西辞采纳,获得10
8秒前
时尚的醉波完成签到 ,获得积分10
8秒前
骑着蜗牛撵大象完成签到 ,获得积分10
9秒前
10秒前
10秒前
上官若男的应助被ooo采纳,获得10
11秒前
believe完成签到,获得积分10
11秒前
哈基米发布了新的文献求助30
12秒前
12秒前
搜集达人的应助被jing采纳,获得10
12秒前
13秒前
13秒前
秋风的应助被这题不讲采纳,获得10
14秒前
麻辣小龙虾完成签到,获得积分10
15秒前
Judy发布了新的文献求助10
15秒前
秋风的应助被DW采纳,获得10
15秒前
16秒前
believe发布了新的文献求助10
17秒前
booniu完成签到,获得积分10
17秒前
18秒前
18秒前
18秒前
一如初见发布了新的文献求助10
18秒前
19秒前
19秒前
2AECML完成签到,获得积分10
19秒前
哈哈发布了新的文献求助10
20秒前
molihuakai的应助被bml采纳,获得10
20秒前
无花果的应助被危机的友易采纳,获得10
20秒前
21秒前
L山间葱发布了新的文献求助10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188295
求助须知:如何正确求助?哪些是违规求助? 9576112
关于积分的说明 21845392
捐赠科研通 7786320
什么是DOI,文献DOI怎么找? 3435276
关于科研通互助平台的介绍 2559581
邀请新用户注册赠送积分活动 2482182